Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of RGX-202-01 (Ompenaclid) , a Small Molecule Inhibitor of the Creatine Transporter SLC6a8, as a Single Agent and as Combination Therapy in Patients With Advanced Gastrointestinal Malignancies With Select Expansion Cohorts

NCT03597581 is registered in ClinicalTrials.gov with Inspirna, Inc. as lead sponsor.

NCT NCT03597581
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03597581 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of RGX-202-01 (Ompenaclid) , a Small Molecule Inhibitor of the Creatine Transporter SLC6a8, as a Single Agent and as Combination Therapy in Patients With Advanced Gastrointestinal Malignancies With Select Expansion Cohorts
Lead sponsor
Inspirna, Inc.
Phase
Phase 1
Overall status
Completed
Start date
June 5, 2018
Completion date
March 31, 2025
Enrollment
89 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, colorectal cancer metastatic, colorectal carcinoma, colorectal neoplasms, crc, gastric cancer, gastric neoplasm, gastrointestinal cancer, gastrointestinal neoplasms, kras mutation-related tumors